Medigene AG (VIE:MDG2)
Austria
· Delayed Price · Currency is EUR 0.0342
-0.0058 (-14.50%)
At close: Nov 18, 2025
Medigene AG Company Description
Medigene AG is in the process of liquidation of its remaining assets. Previously, the company was engaged in the development of T-cell therapies for the treatment of cancer. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.
Medigene AG
| Country | Germany |
| Founded | 1994 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 76 |
| CEO | Ralph Schafer |
Contact Details
Address: Lochhamer Strasse 11 Munich, 82152 Germany | |
| Phone | 49 89 2000 330 |
| Website | medigene.com |
Stock Details
| Ticker Symbol | MDG2 |
| Exchange | Vienna Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ralph Schafer | Chief Executive Officer |
| Birger Kohlert | Chief Financial Officer |
| Pamela Keck | Head of Investor Relations |